Advancing Science.
Designing Hope.
Welcome
At iTeos, we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.
Our three Immuno-Oncology programs each target a key cancer resistance mechanism that inhibits an effective antitumor response: TIGIT, ENT1 and TREM2.
Discover more about each program by clicking the tabs above.
The iTeos Vision
Driven by a culture of scientific innovation, collaboration, and excellence, together we discover, develop, and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.